APIDRA

ApprovedSmall molecule

AAzienda U.S.L. 1 di Massa e Carrara

APIDRA is one of 169 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.

Indications

Total Trials

Active Trials

168

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusApproved

Oxidative StressActive, not recruiting

HyperglycemiaActive, not recruiting

Type 2 DiabetesActive, not recruiting

Type 1 DiabetesActive, not recruiting

Type 1 Diabetes MellitusApproved

Type 2 Diabetes MellitusApproved

Approved

Oxidative StressApproved

Active, not recruiting

HyperglycemiaPreclinical

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Type 1 DiabetesApproved

Active, not recruiting

Type 1 Diabetes MellitusApproved

Approved

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

APIDRA

AAzienda U.S.L. 1 di Massa e Carrara

Approved

1 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

Glargine

Eli Lilly

Preclinical

8 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Aurlumyn

BBTG International Inc.

Preclinical

1 6

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 7

Forxiga

AstraZeneca

Preclinical

3 8

Lovaza

AstraZeneca

Preclinical

1 9

Acipimox

Boehringer Ingelheim

Preclinical

2 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes

Terminated·—·Phase 4·NCT02048189·14 enrolled

Type 1 Diabetes1 trial

Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)

Completed·KKinderkrankenhaus auf der Bult·Phase 4·NCT02914886·14 enrolled

Hyperglycemia1 trial

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

Completed·UUniversity of Florida·N/A·NCT01621776·107 enrolled

Oxidative Stress1 trial

Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)

Completed·FFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud·Phase 4·NCT03328845·300 enrolled

ART1 trial

Self Titration With Apidra to Reach Target Study (START)

Completed· Sanofi logo

Sanofi·Phase 4·NCT01013571·493 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 16, 2004

APIDRA

BLA BLA021629

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for APIDRA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APIDRA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APIDRA. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA021629). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Azienda U.S.L. 1 di Massa e Carrara company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAzienda U.S.L. 1 di Massa e Carrara

APIDRA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes1 trial

Type 1 Diabetes1 trial

Hyperglycemia1 trial

Oxidative Stress1 trial

ART1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News